Timeline
Seagate Technology
Shield Therapeutics narrows H1 loss as revenue jumps 42%
Shield Therapeutics grows H1 revenue 41% on commercial pivot
Shield Therapeutics pediatric trial results published in journal
Shield Therapeutics reports 54% growth in ACCRUFeR sales, but warns over impact of Medicaid changes
Shield Therapeutics partner MEDLEAP confirms first patient enrollment in Japan Phase II for ACCRUFeR
More in Pharma
hVIVO buys CRS Berlin in earnings-accretive deal
It has acquired CRS Berlin for a nominal upfront payment plus a revenue-based earnout, adding dermatology and women's health capabilities to its clinical trials network.